Immunotherapy for Genitourinary Cancers

Published January 17, 2016 | By GRACE Video

IO_2015_Genitourinary_Prostate_Bladder_Kidney_Cancer_Immunotherapy

Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.

What is Immunotherapy & Its Mechanisms of Action? January 13, 2016
Immunotherapy for Lung Cancer January 18, 2016
Novel Immunotherapies and Combinations January 21, 2016
The Current Role of Immunotherapy in the Treatment of… January 14, 2016
Immunotherapy for Melanoma January 19, 2016

Posted in Bladder Cancer, Cancer Treatments, Current Clinical Trials, GRACECast, Immunotherapy, Kidney Cancer (RCC), Treatments & Symptom Management, Webinar | Tagged genitourinary cancer, GM-CSF, immunotherapy, IMPACT trial, James Gulley, National Cancer Institute, PD-1, PD-L1, PROSPECT trial, Prostvac, Provenge, PSA, sipuleucel-T, therapeutic vaccines, tumor markers


Follow us on...	Mission \| Disclaimer	Profile \| GRACEcasts \| DONATE

Copyright ©2018 GRACE - All Rights Reserved

Search cancerGRACE.org

Immunotherapy for Genitourinary Cancers

Related Posts:

GRACE Is Here To Help

Archives

Recent Posts

Recent Comments

Other Resources